Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Operating Leases (2021 - 2025)

Sutro Biopharma's Operating Leases history spans 5 years, with the latest figure at $9.7 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 45.07% year-over-year to $9.7 million; the TTM value through Sep 2025 reached $9.7 million, down 45.07%, while the annual FY2024 figure was $15.7 million, 32.31% down from the prior year.
  • Operating Leases for Q3 2025 was $9.7 million at Sutro Biopharma, down from $11.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $32.1 million in Q3 2021 and bottomed at $9.7 million in Q3 2025.
  • The 5-year median for Operating Leases is $24.9 million (2023), against an average of $23.5 million.
  • The largest annual shift saw Operating Leases decreased 3.23% in 2022 before it tumbled 45.07% in 2025.
  • A 5-year view of Operating Leases shows it stood at $31.2 million in 2021, then decreased by 5.28% to $29.6 million in 2022, then decreased by 21.71% to $23.2 million in 2023, then plummeted by 32.31% to $15.7 million in 2024, then crashed by 38.11% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Operating Leases are $9.7 million (Q3 2025), $11.5 million (Q2 2025), and $13.6 million (Q1 2025).